• NSAID-Induced GI
Toxicity
• Updates in the Management
of Chronic Constipation
• Effective Management
of Ulcerative Colitis


Barrett's Esophagus and Adenocarcinoma
Purpose
This program has been developed to keep gastroenterologists and other healthcare providers abreast of current literature and new developments regarding early detection of Barrett's esophagus.


 
Program Overview
Barrett's esophagus is a premalignant lesion of esophageal adenocarcinoma, and the incidence of esophageal adenocarcinoma is on the rise. Early detection improves survival from this cancer.


 
Audience
This program has been developed to update and educate gastroenterologists and primary care physicians who provide care for people with gastrointestinal conditions.


 
Learning Objectives
Following completion of this CME activity, participants should be better able to:
  • Identify the risk factors for developing Barrett's esophagus.
  • Understand the various diagnostic procedures for Barrett's esophagus.
  • Understand and use the current guidelines for the surveillance of Barrett's esophagus.
  • Relate the development of adenocarcinoma to Barrett's esophagus.


 
Disclaimer
The views expressed herein, while consistent with current medical literature, are solely those of the faculty.


 
Faculty
P. Jay Pasricha, MD (Program Director)
Professor of Anatomy and Neurosciences and Biomedical Engineering
University of Texas Medical Branch
>> Read Biography

Emmet B. Keeffe, MD (moderator)
Professor of Medicine
Stanford University School of Medicine
>> Read Biography

Prateek Sharma, MD
Associate Professor of Medicine
University of Kansas School of Medicine
>> Read Biography

Stuart Jon Spechler, MD
Professor of Medicine
University of Texas Southwestern Medical Center at Dallas
>> Read Biography



 
Faculty Disclosure Information

It is the policy of the AGA to assure balance, independence, objectivity and scientific rigor in all of its directly and jointly sponsored educational activities. All faculty including program committee chairs and planning members participating in any AGA sponsored or jointly-sponsored activity are expected to disclose to the participants any relevant financial relationship or other relationship held within the past 12 months that may pose a potential commercial bias. In accordance with the Accreditation Council for Continuing Medical Education Standards for Commercial Support, faculty members for this activity were each asked to complete financial disclosure forms. Disclosures are provided below.

P. Jay Pasricha, MD
Grant/Research Support: Olympus
Consultant: USGI, GI Supply

Emmet B. Keeffe, MD
Nothing to Disclose

Prateek Sharma, MD
Grant/Research Support: AstraZeneca, Janssen, Ethicon
Speakers' Bureau: AstraZeneca, Janssen, Wyeth, TAP Pharmaceutical Products, Inc.

Stuart Jon Spechler, MD
Speaker's Bureau: AstraZeneca, Janssen, TAP Pharmaceutical Products, Inc.
Grant Support: AstraZeneca



 
Suggested Minimum Software Requirements
Internet Explorer (4.0 or greater), Windows 98 and Windows Media Player (7.0 or greater), or Adobe Acrobat (5.0 or greater)


 
Release Date
May 14, 2005


 
Expiration Date
May 14, 2007


 
Fee
Free-of-charge


 


 
Sponsorship and Support
Sponsored by the AGA. Supported through an educational grant from TAP Pharmaceutical Products, Inc.


 





 


 


 
Launch Multimedia Format
About Us  -  Privacy Policy  -  Disclaimer  -  Editorial & Sponsorship Policy  -  Contact Us  -  CME Café Updates